意大利当地卫生局对生物仿制药消费的分析
Francesco Ferrara1, Maurizio Capuozzo2, Roberto Langella3
1Pharmacy Department, Asl Napoli 3 Sud, Dell'amicizia Street 22, 80035, Naples, Nola, Italy. ferrarafr@libero.it.
Naunyn-Schmiedeberg's archives of pharmacology
|January 17, 2024
概括
生物类似药物的使用量在2022年增加,为医疗保健系统带来了显著的成本节约. 尽管取得了进展,但一些高成本的原始药物,如阿达利穆马布和埃坦纳塞普特,仍然对生物类似药的采用表现出抵抗力.
科学领域:
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
- 药物使用研究 药物使用研究
背景情况:
- 生物类似药物为全球医疗保健系统提供了节省成本的机会.
- 确保同等的有效性和安全性,生物仿制药支持慢性疾病治疗的创新.
- 分析重点是意大利医疗保健环境中的生物类似药物使用.
研究的目的:
- 分析跨治疗领域主要生物类似药物的使用情况.
- 为了比较2022年与2021年的生物类似药物消费和支出.
- 确定生物类似药物全面采用的障碍.
主要方法:
- 从医疗保健数据库中提取有关消费,支出和患者数量的数据.
- 对活性成分利用模式的分析.
- 2021年和2022年数据之间的比较分析.
主要成果:
- 在2022年,大量分析的活性成分被用作生物类似药.
- 对于Adalimumab和Etanercept的原始药物的开支超过了200万欧元.
- 在2021年至2022年期间,生物类似药物使用量同比增加.
结论:
- 增加生物类似药的采用对国家医疗保健系统 (NHS) 和公民都有好处.
- 完全利用生物类似药物是可以实现的,并促进可持续的医疗保健政策.
- 解决对特定原始药物的耐药性是最大化生物类似药益处的关键.
相关概念视频
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Analysis of Population Pharmacokinetic Data
263
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
263
Pharmacovigilance
835
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
835
Bioavailability: Overview
2.8K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
129
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
129
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
64
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
64


